US RAC recommends approval of clinical protocol for first human test of ViroMed's VM202

Published: 2006-08-21 06:56:00

Updated: 2006-08-21 06:56:00

Viromed, a local biotech company, said on August 17 that the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) has voted unanimously that the first human clinical study of ViroMed' gene therapy, a new naked DNA vector, for the treatment of cardiovascular disease ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK